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Abstract Hemicrania continua (HC) and new daily-per-
sistent headache (NDPH) represent the only two forms
of chronic daily headache in Chap. IV ‘‘Other Primary
Headaches’’ of the second edition of the International
Classification of Headache Disorders. HC and NDPH are
rare and poorly defined from a pathophysiological point of
view; as a consequence, their management is largely
empirical. Indeed, there is a lack of prospective, controlled
trials in this field, and treatment effectiveness is basically
inferred from the results of sparse open-label trials, retro-
spective case series, clinical experience and expert opinions.
In this narrative review we have summarised the information
collected from an extensive analysis of the literature on the
treatment of HC and NDPH in order to provide the best
available and up-to-date evidence for the management of
these two rare forms of primary headache. Indomethacin is
the mainstay of HC management. The reported effective
dose of indomethacin ranges from 50 to 300 mg/day.
Gabapentin 600–3,600 mg tid, topiramate 100 mg bid, and
celecoxib 200–400 mg represent the most interesting alter-
native choices in the patients who do not tolerate indo-
methacin or who have contraindications to its use. NDPH is
very difficult to treat and it responds poorly only to first-line
options used for migraine or tension-type headache.
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Background
Hemicrania continua (HC) and new daily-persistent head-
ache (NDPH) represent the only two forms of chronic,
daily headache in Chap. IV ‘‘Other Primary Headaches’’ of
the second edition of the International Classification of
Headache Disorders (ICHD-II) [1]. The chronic temporal
pattern differentiates these two forms from the other types
included in Chap. IV, which are episodic and/or short-
lasting headache and rarely require a prolonged treatment.
Hemicrania continua (HC) and NDPH are rare and
poorly defined from a pathophysiological point of view. As
a consequence, the management of HC and NDPH is lar-
gely empirical. Indeed, there is a lack of prospective,
controlled trials in this field, and treatment effectiveness is
basically inferred from the results of sparse open-label
trials, retrospective case series, clinical experience and
expert opinions. The only available guidelines for the
therapy of HC and NDPH are not available in English and
have been released soon after the publication of ICHD-II,
thus including cases mainly diagnosed with other diag-
nostic criteria [2].
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In this narrative review we have summarised the infor-
mation collected from an extensive analysis of the litera-
ture on the treatment of HC and NDPH in order to provide
the best available and up-to-date evidence for the man-
agement of these two rare forms of primary headache.
Hemicrania continua
Clinical features, diagnostic criteria, epidemiology and
pathophysiology
Hemicrania continua (HC) is an uncommon primary
headache disorder, first described as a syndrome by
Sjaastad and Spierings in 1984 [3]. Hemicrania continua is
a strictly unilateral, continuous, moderate-to-severe head-
ache that fluctuates in intensity with possible exacerbations
of severe pain associated with autonomic disturbances
(conjunctival injection and/or lacrimation, nasal congestion
and/or rhinorrhoea, ptosis and/or miosis); it is absolutely
responsive to indomethacin (Table 1, diagnostic criteria).
Migrainous features and jab-and-jolt pain may also be
present [4]. Hemicrania continua is usually unremitting,
but rare cases of remission have been reported. It is prob-
ably less uncommon than thought in the past [4]. In
the Va˚ga˚ study of headache epidemiology [5], up to 1% of
the individuals surveyed exhibited a clinical picture that
seemed to resemble HC but the diagnosis could not be
confirmed for the compliance problems of the study (dif-
ficult to assess the response to indomethacin).
Different classification systems have been proposed for
HC [6, 7]. Universally accepted operational diagnostic
criteria for HC are contained in the ICHD-II and include, as
an obligatory criterion, an absolute response to therapeutic
doses of indomethacin. However, this criterion has been
criticised because HC may also respond to other drugs,
although less effectively, and also because it means that HC
cannot be diagnosed in patients who have never been
administered this drug [7]. Very recently, Murmura et al.
[8], in a retrospective study, reported that most patient with
a clinical phenotype leading to a putative diagnosis of HC
do not respond to indomethacin. The fact that HC is
included in Chap. IV of ICHD-II, ‘‘Other primary head-
aches’’, reflects its uncertain nosological status. Indeed, the
clinical phenotype of HC overlaps that of trigeminal auto-
nomic cephalalgias and migraine, possibly because it shares
a pathophysiological mechanism with these two conditions
[9, 10]. The inclusion of HC among the primary chronic
headache disorders (CHDs) has been criticised on the
grounds that aside from the chronicity, a highly unspecific
quality, HC is a headache condition showing a sharply
delineated unilaterality and clear therapeutic profile [11].
From a practical point of view, it may indeed be helpful to
consider HC as one of the possible causes of chronic daily
headache (CDH). Early administration of the ‘‘indotest’’ (a
diagnostic test to detect indomethacin-responsive head-
aches) to all cases of chronic unilateral headache may lead
to the timely identification of cases of HC [4].
Early diagnosis of HC is mandatory because the con-
dition can be highly disabling and treatment with indo-
methacin may help patients to achieve a pain-free state.
The diagnostic indotest involves injection of indomethacin
50 mg i.m. and measurement of time for complete pain
relief. In 12 HC patients, complete pain relief was achieved
2 h after this injection [12]. The test is simple and may also
be helpful in identifying atypical cases [13].
Treatment
Indomethacin is the mainstay of HC management. The
mechanism by which it exerts its effect on HC and other
primary headaches is unclear. The reported effective dose of
indomethacin for HC ranges from 50 to 300 mg a day [3, 14].
It is advisable to start with 25 mg tid. The response to
Table 1 International
Headache Society diagnostic
criteria for hemicrania continua
From [1]
Description: persistent strictly unilateral headache responsive to indomethacin
Diagnostic criteria
A. Headache for [3 months fulfilling criteria B–D
B. All of the following characteristics
1. Unilateral pain without side shift
2. Daily and continuous, without pain-free periods
3. Moderate intensity, but with exacerbations of severe pain
C. At least one of the following autonomic features occurs during exacerbations and ipsilateral to the
side of pain
1. Conjunctival injection and/or lacrimation
2. Nasal congestion and/or rhinorrhoea
3. Ptosis and/or miosis
D. Complete response to therapeutic doses of indomethacin
E. Not attributed to another disorder
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indomethacin is prompt. Most patients report complete relief
of headache within 24 h. After one week, if the patient is
asymptomatic, the dose should be decreased to the minimum
effective dose at which the patient remains pain-free. If, on
the other hand, there is no satisfactory response, the dose
should be increased to 50 mg tid. Occasional patients
require higher doses. Gastroprotectors are required to con-
trol gastrointestinal side effects of indomethacin and to
prevent gastroduodenal ulcers. Because remitting forms
have been described, after 3–6 months all patients should try
to decrease the daily dose of indomethacin by 25 mg each
week until discontinuation, unless the symptoms reappear.
Hemicrania continua is often a lifelong condition, rais-
ing the issue of loss of therapeutic efficacy over time and
potential long-term side effects. Indomethacin does not
seem to show tachyphylaxis. On the contrary, Pareja et al.
[6] showed that, over time, 42% of patients were able to
decrease, by up to 60%, the dose of indomethacin required
to maintain a pain-free state. As regards the long-term
tolerability of indomethacin, of 12 HC patients followed
up for varying periods of between 1 and 11 years, 23%
experienced minor side effects, mostly gastrointestinal
problems relieved with gastroprotectors [4]. In the litera-
ture, more than 35% of patients receiving therapeutic
dosages of indomethacin experience adverse effects and
20% have to discontinue the drug [15]. Most adverse
effects are dose-related, which underlines the importance
of achieving the lowest effective dose. Gastrointestinal
complications, such as anorexia, nausea, vomiting, dys-
pepsia, abdominal pain, mucosal ulceration and diarrhoea
are the most frequent adverse effects but they are not often
a cause for discontinuation. Indomethacin is contraindi-
cated in conditions, such as renal failure, gastric ulcers and
bleeding disorders. The risks associated with long-term
indomethacin use include gastrointestinal ulcers and renal
dysfunction, such as papillary necrosis. The first described
HC patient was followed up for 19 years and developed
bleeding gastric ulcer, treated with gastric surgery [16].
Patients who cannot tolerate indomethacin present a
major challenge as regards the management of their head-
ache, as no other drug has been shown to be consistently
effective in HC. However, anecdotal observations suggest
that drugs other than indomethacin may be helpful in HC.
Sjaastad and Antonaci [17] reported a complete response to
piroxicam beta-cyclodestrin 20 to 40 mg/day in 4 out of 6
patients (1 had a moderate response and 1 had no response).
Selective COX-2 inhibitors, rofecoxib (50 mg/day) and
celecoxib (200–400 mg bid), were found to be highly
effective in 3 out of 9 patients and 3 out of 5 patients [18],
respectively (1 patient receiving celecoxib and 5 of those
receiving rofecoxib experienced a partial response). The
COX-2 inhibitors have been proposed as an alternative to
indomethacin in HC and other indomethacin-responsive
syndromes [18, 19], but their long-term use has recently been
associated with an increased risk of myocardial infarction
and stroke, and rofecoxib has been withdrawn from the
market worldwide [20]. Indeed, an increased risk of car-
diovascular events exists with non-steroideal anti-inflam-
matory drugs in general, indomethacin included, and patients
with cardiovascular disease should be informed about this
risk and considered for alternative therapeutic options [21].
Rozen [22] described 3 patients responding to melatonin (9–
15 mg/day), which has a similar chemical structure to
indomethacin. In two cases melatonin alone was sufficient to
achieve a pain-free state while in the third case it made it
possible to reduce the total dose of indomethacin by 50%.
Another case responding to melatonin 7 mg at bedtime was
described by Spears [23], and there have recently been
descriptions of five cases (two with atypical features)
responding to topiramate (100 mg bid), and of a single
patient with HC evolving from CH responding to valproic
acid [24–27]. Very recently, Spears reported the efficacy of
gabapentin in 9 HC patients who had difficulties in tolerating
indomethacin [28]. Seven patients reported a 50–80%
reduction of pain with doses ranging from 900 to 3,600 mg/
day (two of them used other medication for pain control).
One patient reported a 50% reduction of pain and one
reported no effect. Four patients were pain free on gaba-
pentin (600–1,800 mg/day).
Isolated case reports have described ibuprofen,
naproxen, aspirin, paracetamol with caffeine and verapamil
as effective [29, 30], but most of these drugs have been
found to be ineffective in other HC cases.
Other classes of drug have not been successful in con-
trolling HC. Antonaci et al. [31] reported a lack of efficacy
of sumatriptan in 7 patients. Because HC is widely mis-
diagnosed, patients are prescribed many classes of drugs,
often ones effective in migraine (such as analgesics, cal-
cium-antagonists, beta-blockers, amitriptyline and other
antidepressants, antiepileptics, ergot derivatives, pizotifen,
methysergide) as well as others that are reported to be of no
benefit in migraine [32].
Anaesthetic blockades of pericranial nerves have been
found to be ineffective [33].
Very recently, Schwedt et al. and Burns et al. [34, 35]
reported that occipital nerve stimulation may be a safe and
effective treatment for HC (8 cases) at short- and long-term
follow-up.
To review the problems linked to the misdiagnosis and
mismanagement of HC patients we recently interviewed 25
consecutive HC subjects attending the Headache Clinic INI
Grottaferrata [36]. Patients were asked about their use of
pharmacological treatments, surgical treatments and non-
pharmacological treatments for headache and to rate the
effectiveness of each treatment on a four-point scale (very
effective, i.e. complete and long-lasting relief; effective,
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i.e. partial and/or short-lasting relief; ineffective; headache
worsened). The patients had tried a mean of 3.63 ± 2.1
different classes of drug (67% prescribed, 33% unpre-
scribed). NSAIDs had been tried by 92%. Nimesulide (a
non-steroideal anti-inflammatory drug not available on the
market in US and in the majority of EU countries) had been
tried by 7 patients and been judged very effective by one
and effective by six. Aspirin and ibuprofen had each been
tried by 9 patients and were rated as effective by five and
three of them, respectively. Antidepressants had been used
by 8 patients (6 amitriptyline, 2 fluoxetine) but showed
no effectiveness. Triptans had been used by 8 patients (5
sumatriptan s.c., 1 zolmitriptan and 2 rizatriptan) and been
judged ineffective by all of them. Two patients had used
rofecoxib and considered it very effective. Taken together,
these HC patients had used a cumulative total of 80 dif-
ferent drug treatments, judging 73.7% of these medications
ineffective, 22.5% partially effective (all NSAIDs) and
3.75% (rofecoxib and nimesulide) effective.
As much as 36% of the patients had undergone inef-
fective and unnecessary surgery (dental extraction, sinus/
deviated septum surgery, temporomandibular joint surgery
and cervical spine surgery) for their HC. Four patients
had tried acupuncture (two considering it effective) and
four had tried homeopathy (deemed ineffective by all of
them).
These data suggest that HC is largely mismanaged as
a consequence of its misdiagnosis. Indeed, apart from
NSAIDs which, as a rule, were not prescribed, patients
were mainly prescribed, by physicians, medications shown
to be effective in the treatment of migraine or cluster
headache but ineffective for HC.
Hemicrania continua may be complicated by overuse of
symptomatic drugs [8, 37] and (in this situation) differen-
tial diagnosis of HC versus transformed or chronic
migraine may be difficult. An exhaustive disease history
could be helpful, as it may show a pre-existing unilateral
primary headache. However, the overused medication
should always be withdrawn and, if the headache persists,
the indomethacin response should be tested.
Figure 1 sets out a schematic approach to the manage-
ment of HC.
First choice 
Indomethacin 50-300 mg 
• Start with 25 mg tid with me als and increase the dosage gradually until complete pain 
relief is obtained 
• Treatment failure should be considered if a patient fails to respond to a daily dosage of 300 
mg (consider alternative diagnosis) 
• Once an effective dosage has been established for several weeks, reduce the dosage to 
ascertain the lowest effective dosage 
• Prescribe gastroprotectors to prevent and manage gastrointestinal side effects 
• Check renal function regularly 
Alternative choices  (patients not tolerating or presenting contraindications to 
indomethacin) 
• Consider celecoxib (200-400 mg bid) 
      If not effective 
• Consider topiramate (100 mg bid)  or gabapentin (600-3600 mg tid) or melatonin (7-15 
mg at bedtime)
Refractory cases 
• Consider occipital nerve stimulation  
Fig. 1 A schematic approach to
the management of hemicrania
continua
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New daily-persistent headache (NDPH)
Clinical features, diagnostic criteria, epidemiology and
pathophysiology
New daily-persistent headache (NDPH) is characterised by
the abrupt onset of persistent headache that generally
develops over \3 days and does not remit (Table 2, diag-
nostic criteria). In isolated reports on this entity, NDPH
has been interpreted as a post-viral syndrome [38] and
described as having a spontaneously favourable outcome
[39]. On the basis of retrospective clinical observations,
Silberstein et al. [40] included NDPH as a separate clinical
entity in their classification of CDH and provided opera-
tional diagnostic criteria for the condition [briefly, they
included: (a) average headache frequency[15 days/month
for [1 month, (b) average headache duration [4 h/day, if
untreated, (c) no history of migraine or TTH increasing in
frequency or decreasing in severity in association with the
onset of NDPH, (d) acute onset—developing over 3 days—
of constant unremitting headache and exclusion of sec-
ondary headache]. In ICHD-II, NDPH is included in Chap.
IV, ‘‘Other primary headaches’’, underlining its uncertain
nosological status. According to these International Head-
ache Society diagnostic criteria, NDPH is phenotypically
reminiscent of tension-type headache (TTH), i.e. a sort of
de novo chronic TTH (CTTH). However, NDPH is unique
in that the headache is daily and unremitting from or
almost from the moment of onset, and occurs typically in
individuals without a prior headache history, which sug-
gests that the pathogenetic mechanisms in NDPH and
CTTH are different.
In a recent clinic-based study conducted in a paediatric
population, using a modified version of the ICHD-II cri-
teria, NDPH was more common than CTTH and most of
the subjects with NDPH did not overuse medication and
commonly presented migrainous features [41].
New daily-persistent headache (NDPH) is probably a
heterogeneous disorder and should therefore be regarded
as a syndrome. A viral infection or other organic cause
may precede the headache in more than one-third of
patients [42], possibly leading to a CNS inflammation and
sensitisation of nociceptive pathways [43]. In some
patients, cervical spine joint hypermobility may be a
factor predisposing to the development of NDPH [44].
NDPH has a wide range of secondary forms that have to
be excluded after thorough diagnostic work-up [45]. In
these cases the causes (e.g. spontaneous intracranial
hypotension, neoplasms, pseudotumour cerebri, cervical
artery dissections, cerebral venous thrombosis, Chiari I
malformation and temporal arteritis) can be treated and
should be carefully excluded before a headache manage-
ment plan is worked out [45]. The prognosis of NDPH
is highly variable, ranging from self-limiting cases
that typically resolve without therapy within several
months to refractory cases resistant to aggressive treat-
ment programmes.
Further pathophysiological and clinical characterisation
of this syndrome is necessary so that the management of
NDPH can be based on a clear rationale and on specific
treatment options and general recommendation can be
given. Empirical evidence on NDPH therapy is poor and
based on the application of treatments that have proved to
be effective in migraine or TTH. No prospective, placebo-
controlled trial has been conducted in this field and the
effectiveness of treatment can only be inferred, from the
results of a few open-label trials, retrospective case
reviews, anecdotal observations, expert opinions and gen-







Headache that is daily and unremitting from very soon after onset (within 3 days at most). The pain is
typically bilateral, pressing or tightening in quality and of mild to moderate intensity. There may be
photophobia, phonophobia or mild nausea
Diagnostic criteria
A. Headache that, within 3 days of onset, fulfils criteria B-D
B. Headache is present daily, and is unremitting, for [3 months
C. At least two of the following pain characteristics
1. Bilateral location
2. Pressing/tightening (non-pulsating) quality
3. Mild or moderate intensity
4. Not aggravated by routine physical activity such as walking or climbing stairs
D. Both of the following
1. No more than one of photophobia, phonophobia or mild nausea
2. Neither moderate or severe nausea nor vomiting
E. Not attributed to another disorder
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Treatment
The largest uncontrolled study investigating the effective-
ness of drug therapy and the prognosis of NDPH diagnosed
according to the ICHD-II criteria was conducted in Japan
by Takase et al. [46]. In 30 NDPH patients (17 males) the
authors first administered muscle relaxants. If no effect was
observed, tricyclic antidepressants (23 patients), valproic
acid (9 patients), SSRIs (12 patients) and beta-blockers
(2 patients) were subsequently administered. Drug treat-
ment was rated as very effective by 27% of patients,
moderately effective by 3%, mildly effective by 20% and
ineffective by 50%. The authors concluded that NDPH has
a poor prognosis and is highly resistant to currently
available treatments.
Meineri et al. [47] retrospectively evaluated the effec-
tiveness of drug therapy in 18 NDPH patients (the authors
used both ICHD-II and Silberstein-Lipton’s criteria). Six-
teen patients tried amitriptyline, seven tried fluoxetine and
seven tried valproic acid. The authors reported that no drug
was effective.
In a small American case series of NDPH patients
diagnosed according to the Silberstein and Lipton criteria,
the following drugs were reported to be effective: gaba-
pentin (1 case, 2,700 mg/day), topiramate (1 case, 150 mg/
day), venlafaxine (1 case, 75 mg/day) and nortriptyline (1
case, 100 mg/day) [48]. In these cases the therapeutic
effectiveness was achieved after the patients had tried
many first-line drugs for migraine and CTTH. Marmura
et al. [49] recently reported 3 patients with NDPH (two of
which were overusing symptomatic drugs) who experi-
enced significant improvement with mexiletine (1,050–
1,200 mg) after having failed on multiple appropriate
preventive treatments. All of these patients experienced
side effects, such as nausea, fatigue, tremor and dizziness,
which were reported to be dose-dependent. An isolated
report has documented the effectiveness of botulinum toxin
A [50].
Like other chronic daily headaches, NDPH may be
complicated by medication overuse. Physicians are advised
to ascertain a patient’s complete medication history before
starting any therapy. If medication overuse is diagnosed,
drug withdrawal is necessary before other therapeutic
options can be tried even though no prospective study has
specifically investigated the effect of medication overuse in
the worsening and maintenance of NDPH or in the deter-
mining of a resistance to therapy.
In summary, NDPH seems to be difficult to treat and to
respond only poorly to first-line options used for migraine
or TTH. Well-designed, targeted clinical trials considering
the heterogeneity of this clinical entity, are needed so that
an evidence-based therapy can be developed for this poorly
characterised clinical syndrome.
Conflict of interest None.
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